31st Jan 2023 14:32
Ondine Biomedical Inc - Canadian life sciences company focused in the field of photodisinfection therapies - Steriwave, Ondine's nasal photodisinfection therapy, has been found to improve short- and long-term immune responses while also "significantly" reducing SARS-CoV-2 infectivity. This effect was detectable not only in antibody-mediated immunity, but also in T-cell mediated immunity.
Chief Executive Officer Carolyn Cross says: "The Clinica Universidad de Navarra study sheds new light on the photodisinfection treatment of respiratory viruses, where antibiotics are entirely ineffective and new anti-viral therapies are limited. As new SARS-CoV-2 variants rapidly emerge across the globe, we look forward to being able to play our part in helping our communities, hospitals, clinics, and emergency workers deal with these new threats."
Current stock price: 20.73 pence, up 9.1% in London on Tuesday
12 month change: down 62%
By Holly Beveridge; Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ondine Biomed